Senseonics Expects $34M-$38M in FY25 Revenue, Consensus at $35.9M

Senseonics has backed its FY25 revenue view to $34M-$38M, in line with the consensus of $35.9M. The company expects a doubling of its global patient base during 2025, with revenue weighted towards the second half of the year due to Eversense 365's once-a-year reorder dynamics. Gross margins are expected to increase throughout 2025, with a range of 32.5%-37.5%. Cash used in operations in 2025 is expected to be approximately $60 million.

Senseonics Holdings, Inc. (NYSE American: SENS) has reinforced its fiscal year 2025 (FY25) revenue forecast, projecting a range of $34 million to $38 million. This projection aligns with the consensus estimate of $35.9 million [1]. The company anticipates a doubling of its global patient base during 2025, with revenue expected to be weighted towards the second half of the year due to the once-a-year reorder dynamics of Eversense 365 [2].

The second quarter (Q2) 2025 results showed a 37% year-over-year (YoY) growth in revenue, reaching $6.6 million. This growth was driven by a 79% increase in new patient starts in the U.S. and an expanded direct-to-consumer (DTC) advertising campaign that boosted leads by 50% [2]. The company also achieved a 79% increase in U.S. new patient starts over the prior year, which significantly contributed to the revenue growth [2].

Senseonics' gross margins are projected to increase throughout 2025, with a range of 32.5% to 37.5%. The company expects cash used in operations to be approximately $60 million for the year [2]. The company raised $77.8 million in total gross proceeds, including $57.5 million from a public offering and $20.3 million from Abbott in a concurrent private placement, to fund the ongoing launch of Eversense 365 and continued development of pipeline products [2].

The company's financial outlook is supported by the completion of 365-day product trials, which led to a reduction in research and development (R&D) expenses. Additionally, the company has entered into a commercial development agreement to integrate Sequel Med Tech’s twiist™ automated insulin delivery (AID) system with Eversense 365, with a launch expected in Q4 [2].

Analysts have a "buy" rating on the shares, with an average consensus recommendation of "buy" for the medical equipment, supplies & distribution peer group. The median 12-month price target for Senseonics Holdings Inc. is $1.33, about 61.8% above its August 5 closing price of $0.51 [1].

References:
[1] https://www.tradingview.com/news/reuters.com,2025:newsml_PLX09C542:0-medtech-firm-senseonics-q2-revenue-up-37-net-loss-narrows/
[2] https://finance.yahoo.com/news/senseonics-holdings-inc-reports-second-200500219.html